Pharmacokinetics of XueBiJing in Patients With Sepsis

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Pharmacokinetics and disposition of XueBiJing compounds in patients with sepsis

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Southeast University, China
• Collaborator: Chinese Academy of Sciences

Criteria

Inclusion Criteria:

• 18≤ age ≤70 years old

• Community acquired pneumonia patients who met the Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of Intensive Care Medicine (ESICM) with2 ≤SOFA ≤13

• To use XueBiJing injection as an add-on therapy to treat sepsis decided byclinician

• Informed consent obtained

Exclusion Criteria:

• Diagnosis of sepsis for over 48 h

• Pregnant or lactating women

• Patients with a history of anaphylaxis or allergyto XueBiJing or its component herbs

• Patients participated in an investigational clinical trial within 30 days prior to this study

• Patients unable or unsuitable to participate in this study decided by the investigator (i.e., patients whose death are deemed within 48 h or who poorly adhere to the treatment)